The mass disappeared completely in the bilateral orbital MRI taken after the 5th month of the ibrutinib treatment.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Mantle cell lymphoma is a subtype of B cell non-Hodgkin's lymphoma with different clinical and molecular features.
📊
Temel Bulgular & Veri:Here, we aimed to present a blastoid variant MCL patient who developed orbital recurrence after four lines of systemic therapy and responded to ibrutinib (560 mg/day) monotherapy.
💡
Sonuç & Katkı:The mass disappeared completely in the bilateral orbital MRI taken after the 5th month of the ibrutinib treatment.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri
Abstract
Mantle cell lymphoma is a subtype of B cell non-Hodgkin's lymphoma with different clinical and molecular features. Extranodal involvement is common in MCL. Bone marrow, liver, spleen, waldeyer ring and gastrointestinal involvement are most common. Lymphomatosis polyposis can be seen in some patients. Central nervous system involvement is rare. Here, we aimed to present a blastoid variant MCL patient who developed orbital recurrence after four lines of systemic therapy and responded to ibrutinib (560 mg/day) monotherapy. The mass disappeared completely in the bilateral orbital MRI taken after the 5th month of the ibrutinib treatment.
🔖
Bu Makaleye Atıf Yap
Kaya, E., Bahcecioglu, O. F., Erkurt, M. A., Ulubaba, H. E., Kuku, I., Bicim, S., Sarici, A., Berber, I. (2022). Experience of ibrutinib in a patient with recurrent mantle cell lymphoma with orbital involvement. Medicine Science, Cilt: 10 - Sayı: 4, 1542–1545. https://ajindex.com/articles/579704
Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood 1997;89:2067
Dreyling, M., Geisler C., Hermine O., et al., Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 25 Suppl 3:iii83-92
Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, riskstratification, and clinical management. Am J Hematol. 2017 92:806–13
Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007 7:750–62
Barista I, Romaguera JE, Cabanillas F. Mantle-cell lymphoma. Lancet Oncol. 2001 2:141–8
Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009 94:1555-62
Bertoni F, Zucca E, Cotter FE. Molecular basis of mantle cell lymphoma. Br J Haematol. 2004;124:30
Panayiotidis P, Kotsi P. Genetics of small lymphocyte disorders. Semin Hematol. 1999;36:171
Armitage, J. O., Weisenburger, D. D. New approach to classifying non- Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998 16, 2780-95
Ferrer A, Salaverria I, Bosch F, et al. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer. 2007;109:2473
Bernard M, Gressin R, Lefrère F, et al. Blastic variant of mantle cell lymphoma: A rare but highly aggressive subtype. Leukemia. 2001 15:1785– 91
Rašić DM, Knežević M Terzić T, et al. Bilateral ocular panadnexal mass as initial presentation of systemic blastoid variant of mantle-cell lymphoma. Surv Ophthalmol. 2017 62:83-8
Looi, A., Gascoyne, R. D., Chhanabhai, M., et al. Mantle cell lymphoma in the ocular adnexal region. Ophthalmology, 2005 112,114-9
Knudsen MKH, Rasmssen PK, Coupland SE, et al. Clinicopathological features of ocular adnexal mantle-cell lymphoma in an international multicenter cohort. JAMA Ophthalmol. 2017;135:1367–74
Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687